Listed

CorMedix Inc.

CRMDNasdaqCIK 1410098HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$101.9mRevenue, Q2 FY2026, three months to 2026-06-30$101.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 13, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$101.9mRevenue, Q2 FY2026, three months to 2026-06-30$101.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure+156.5% on a year earlier
  • Gross margin75.7%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $77.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Revenue: $101.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure−19.6 pts on a year earlier
  • Operating margin42.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $42.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Revenue: $101.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure−7.1 pts on a year earlier
  • Net margin25.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $26.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Revenue: $101.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure−24.4 pts on a year earlier
  • Diluted EPS$0.29Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure+3.6% on a year earlier
  • Free cash flow$85.7mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $86.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001410098-26-000056. Derived: 6-month figure less the 3-month figure.Capital expenditure: $561.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001410098-26-000056. Derived: 6-month figure less the 3-month figure.Report this figure+185.9% on a year earlier

Last eight quarters

Full statements
Revenue$101.9mGross margin 75.7%
Diluted EPS$0.29, Q2 FY2026
Free cash flow$85.7m, Q2 FY2026
CorMedix Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m11.5Revenue, Q3 FY2024, three months to 2024-09-30$11.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Report this figure31.2Revenue, Q4 FY2024, three months to 2024-12-31$31.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Report this figure39.1Revenue, Q1 FY2025, three months to 2025-03-31$39.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure39.7Revenue, Q2 FY2025, three months to 2025-06-30$39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure104Revenue, Q3 FY2025, three months to 2025-09-30$104.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Report this figure129Revenue, Q4 FY2025, three months to 2025-12-31$128.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Report this figure127Revenue, Q1 FY2026, three months to 2026-03-31$127.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure102Revenue, Q2 FY2026, three months to 2026-06-30$101.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure
Gross margin%94.0%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $10.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Revenue: $11.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Report this figure96.2%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $30.0m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Revenue: $31.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Report this figure95.9%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $37.5m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Revenue: $39.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure95.3%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $37.9m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Revenue: $39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure89.3%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $93.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Revenue: $104.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Report this figure83.4%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $107.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Revenue: $128.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Report this figure82.5%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $105.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Revenue: $127.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure75.7%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $77.1m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Revenue: $101.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure
Operating margin%(28.7%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$3.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Revenue: $11.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Report this figure41.4%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $12.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Revenue: $31.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Report this figure51.5%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $20.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Revenue: $39.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure49.2%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $19.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Revenue: $39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure49.2%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $51.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Revenue: $104.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Report this figure46.0%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $59.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Revenue: $128.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Report this figure50.0%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $63.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Revenue: $127.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure42.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $42.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Revenue: $101.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure
Net margin%(24.2%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Revenue: $11.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Report this figure43.1%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $13.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Revenue: $31.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Report this figure52.8%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $20.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Revenue: $39.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure49.9%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $19.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Revenue: $39.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure104.1%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $108.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Revenue: $104.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Report this figure10.9%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $14.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Revenue: $128.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Report this figure30.3%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $38.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Revenue: $127.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure25.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $26.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Revenue: $101.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure
Diluted EPS$ per share(0.05)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Report this figurenot reported (Diluted EPS not reported)0.30Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure0.28Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure1.26Diluted EPS, Q3 FY2025, three months to 2025-09-30$1.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001213900-25-108777.Report this figurenot reported (Diluted EPS not reported)0.43Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure0.29Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001410098-26-000056.Report this figure
Free cash flow$m(13.7)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$13.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001213900-25-108777. Derived: 9-month figure less the 6-month figure.Capital expenditure: $9.8k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001213900-25-108777. Derived: 9-month figure less the 6-month figure.Report this figure(5.6)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$5.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Capital expenditure: $10.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Report this figure19.7Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $19.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Capital expenditure: $10.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure30.0Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $30.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001410098-26-000056. Derived: 6-month figure less the 3-month figure.Capital expenditure: $24.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001410098-26-000056. Derived: 6-month figure less the 3-month figure.Report this figure30.4Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $30.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001213900-25-108777. Derived: 9-month figure less the 6-month figure.Capital expenditure: $505.9k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001213900-25-108777. Derived: 9-month figure less the 6-month figure.Report this figure92.7Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $94.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001213900-26-023889. Derived: 12-month figure less the 9-month figure.Report this figure41.7Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $42.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Capital expenditure: $729.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001410098-26-000021.Report this figure85.7Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $86.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001410098-26-000056. Derived: 6-month figure less the 3-month figure.Capital expenditure: $561.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001410098-26-000056. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$311.7mGross margin 88.5%
Diluted EPS$2.04, FY2025
Free cash flow$172.8m, FY2025
CorMedix Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m0.2Revenue, FY2021, twelve months to 2021-12-31$190.9k. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-30, accession 0001213900-23-024310.Report this figure0.1Revenue, FY2022, twelve months to 2022-12-31$65.4k. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-12, accession 0001213900-24-021585.Report this figurenot reported (Revenue not reported)43.5Revenue, FY2024, twelve months to 2024-12-31$43.5m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure312Revenue, FY2025, twelve months to 2025-12-31$311.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure
Gross margin%22.0%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $42.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2023-03-30, accession 0001213900-23-024310.Revenue: $190.9k. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-30, accession 0001213900-23-024310.Report this figure94.3%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $61.7k. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-03-12, accession 0001213900-24-021585.Revenue: $65.4k. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-12, accession 0001213900-24-021585.Report this figurenot reported (Gross profit and Revenue not reported)92.7%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $40.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-05, accession 0001213900-26-023889.Revenue: $43.5m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure88.5%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $275.7m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-05, accession 0001213900-26-023889.Revenue: $311.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure
Operating margin%(15417.5%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$29.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-30, accession 0001213900-23-024310.Revenue: $190.9k. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-30, accession 0001213900-23-024310.Report this figure(46819.9%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$30.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-12, accession 0001213900-24-021585.Revenue: $65.4k. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-12, accession 0001213900-24-021585.Report this figurenot reported (Revenue not reported)(51.4%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$22.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001213900-26-023889.Revenue: $43.5m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure48.2%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $150.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001213900-26-023889.Revenue: $311.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure
Net margin%(14774.7%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$28.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-30, accession 0001213900-23-024310.Revenue: $190.9k. XBRL concept us-gaap:Revenues. 10-K filed 2023-03-30, accession 0001213900-23-024310.Report this figure(45409.9%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$29.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-12, accession 0001213900-24-021585.Revenue: $65.4k. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-12, accession 0001213900-24-021585.Report this figurenot reported (Revenue not reported)(41.2%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$17.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001213900-26-023889.Revenue: $43.5m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure52.3%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $163.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001213900-26-023889.Revenue: $311.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure
Diluted EPS$ per share(0.75)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-30, accession 0001213900-23-024310.Report this figure(0.74)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-12, accession 0001213900-24-021585.Report this figure(0.91)Diluted EPS, FY2023, twelve months to 2023-12-31−$0.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-25, accession 0001013762-25-001852.Report this figure(0.30)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.30 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure2.04Diluted EPS, FY2025, twelve months to 2025-12-31$2.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure
Free cash flow$m(22.6)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$21.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-30, accession 0001213900-23-024310.Capital expenditure: $1.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-30, accession 0001213900-23-024310.Report this figure(24.6)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$24.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-12, accession 0001213900-24-021585.Capital expenditure: $219.4k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-12, accession 0001213900-24-021585.Report this figure(38.7)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$38.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-25, accession 0001013762-25-001852.Capital expenditure: $327.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-25, accession 0001013762-25-001852.Report this figure(50.7)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$50.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001213900-26-023889.Capital expenditure: $116.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure173Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $175.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001213900-26-023889.Capital expenditure: $2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001213900-26-023889.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding CorMedix Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$49.6m6,324,111Added+356,536
Deep Track Capital, LP2026-06-30$49.3m6,274,076Unchanged
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$24.6m3,135,075Added+5,419
STATE STREET CORP2026-06-30$18.2m2,316,845Added+125,002
ROYCE & ASSOCIATES LP2026-06-30$17.1m2,176,362Added+288,830
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$15.3m1,947,014Added+130,107
UBS Group AG2026-06-30$14.7m1,877,940Added+339,695
OBERWEIS ASSET MANAGEMENT INC/2026-06-30$10.4m1,323,915Added+112,800
Alyeska Investment Group, L.P.2026-06-30$6.7m850,000Unchanged
MARSHALL WACE, LLP2026-06-30$6.1m779,535Added+276,570

Recent filings

All 1,125 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

CorMedix Inc., recent filings
FiledFormWhat it isAccession number
2026-10-1912:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-110477
2026-08-1312:07 ET10-QQuarterly reportPeriod 2026-06-300001410098-26-000056
2026-08-1311:32 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001410098-26-000054
2026-08-0720:18 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001410098-26-000044
2026-07-0220:30 ET8-K8.01 Other events0001410098-26-000040
2026-07-0111:14 ET8-K4.01 Change of auditor0001410098-26-000037
2026-06-2420:30 ET8-K5.07 Shareholder vote results0001410098-26-000028
2026-06-0812:45 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-066061
2026-05-1412:00 ET10-QQuarterly reportPeriod 2026-03-310001410098-26-000021
2026-05-1411:34 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001410098-26-000020

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 5, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1410098
Tickers
CRMD
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. Listed shows no prices and gives no investment advice.